October 20, 2020

Dear Healthcare Provider,

The purpose of this letter is to provide an informational update about the potential for a near-term supply interruption of NATPARA® (parathyroid hormone) for Injection that may impact U.S. patients receiving NATPARA 100-mcg through the Special Use Program (SUP). Takeda is notifying SUP-enrolled patients and their healthcare providers of the following time-sensitive actions. If none of your patients are receiving NATPARA 100-mcg through the NATPARA SUP, there is nothing you need to do at this time. Supply status updates for all other NATPARA doses are also included in this letter.

Time-Sensitive Information Regarding Patients Receiving NATPARA 100-mcg

Supply interruption of NATPARA 100-mcg is expected to occur as early as **November 21, 2020.** We are alerting healthcare providers and SUP-enrolled patients who are receiving NATPARA 100-mcg in the event that healthcare providers need to evaluate alternate treatment plans in anticipation of this expected supply interruption. A member of Takeda's OnePath Patient Services team will directly notify impacted patient(s) and advise them to contact their prescribing physician to assess what treatment plan adjustments may be required due to the expected supply interruption of the NATPARA 100-mcg dose.

Ensuring patient safety and supply continuity for patients with hypoparathyroidism are our highest priorities. Available product inventory has been impacted by unexpected manufacturing disruptions that are separate from the issue of rubber particulates originating from the rubber septum of the NATPARA cartridge. We are working with urgency to resolve the manufacturing issues that are affecting the availability of NATPARA 100-mcg. At the same time, we are working on possible mitigation options for impacted patients with U.S. Regulatory Authority (U.S. Food & Drug Administration or "FDA") oversight and will notify healthcare providers of any future approved options for alternate treatment plans.

For any patients who may be affected by a NATPARA dose interruption, we are emphasizing that the patient's prescribing physician should review Section 2.6 (NATPARA Dose Interruption or Discontinuation) and Section 5.4 (Warnings and Precautions: Hypocalcemia) in the attached NATPARA Full Prescribing Information. It is very important to closely monitor serum calcium levels and observe for signs and symptoms of hypocalcemia in these patients while carefully adjusting active vitamin D and supplemental calcium doses. Some patients may require higher doses of active vitamin D and supplemental calcium than doses required prior to starting NATPARA. Additional guidance regarding NATPARA treatment interruption was previously issued in a joint statement by the Endocrine Society and the American Society for Bone and Mineral Research (ASBMR) at the following URL: https://endocrinenews.endocrine.org/endocrine-society-asbmr-issue-joint-statement-on-natpara-recall/.

Update Regarding Patients Receiving NATPARA 25-mcg, 50-mcg or 75-mcg:

At this time, we do **not** expect SUP-enrolled patients who are receiving **NATPARA 25-mcg**, **NATPARA 50-mcg** or **NATPARA 75-mcg** to be impacted by the supply interruptions. However, we are closely monitoring the remaining NATPARA doses (25-mcg, 50-mcg and 75-mcg). We are committed to supply continuity and will provide an update on all NATPARA doses by November 16, 2020. We have communicated this information to patients who are receiving NATPARA through the Special Use Program, and we have emphasized to patients receiving NATPARA 25-mcg, NATPARA 50-mcg or NATPARA 75-mcg that there is nothing that they need to do at this time.

Compliance with Special Use Program Terms & Conditions

It is important to remind SUP-enrolled patients that each NATPARA cartridge under the Special Use Program (single dose use) is intended for one use only, and that used cartridges with remaining product are to be returned to Takeda in accordance with the Special Use Program (single dose use) instructions. Non-compliance with the rules under the Special Use Program (single dose use) could result in termination of the patient's ability to receive NATPARA product through the program.

Reporting Adverse Events
Healthcare providers and patients are encouraged to report adverse events in patients taking NATPARA to Takeda at 1-800-828-2088. You are encouraged to report negative side effects of prescription drugs to the U.S. Food & Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Medical Information
You may also contact our medical information department at 1-800-828-2088 if you have any questions about the information contained in this letter or the safe and effective use of NATPARA.

This letter is not intended as a complete description of the benefits and risks related to the use of NATPARA. Please refer to the enclosed full Prescribing Information and Medication Guide. For additional information, please call Takeda at 1-800-828-2088 or visit www.natpara.com.

We recognize the important medical need that NATPARA fills for your hypoparathyroidism patients. While we focus on mitigating these supply interruptions for SUP-enrolled patients, we continue to prioritize the goal of safely bringing NATPARA back to the broader patient community with U.S. Regulatory Authority oversight.

Sincerely,

Tom Koutsavlis
Head, US Medical

Enclosure: NATPARA Full Prescribing Information

US-NAT-0140v1.0 10/20